Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

Highlights • Brentuximab vedotin available to R/R HL/sALCL patients on Named Patient Program. • We re-evaluated the efficacy and safety of NPP data in a pooled literature analysis. • Overall response rates were 67% in R/R HL and 75% in R/R sALCL. • Complete remission rates were 26% in R/R HL and 74%...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2015-09, Vol.95 (3), p.359-369
Main Authors: Zinzani, P.L, Sasse, S, Radford, J, Shonukan, O, Bonthapally, V
Format: Article
Language:English
Subjects:
Anaplastic large cell lymphoma
Antibody–drug conjugate
Brentuximab vedotin
CD30
Hematology, Oncology and Palliative Medicine
Hodgkin Disease - drug therapy
Hodgkin lymphoma
Humans
Immunoconjugates - adverse effects
Immunoconjugates - therapeutic use
Lymphoma, Large-Cell, Anaplastic - drug therapy
Named Patient Program
Recurrence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Brentuximab vedotin available to R/R HL/sALCL patients on Named Patient Program. • We re-evaluated the efficacy and safety of NPP data in a pooled literature analysis. • Overall response rates were 67% in R/R HL and 75% in R/R sALCL. • Complete remission rates were 26% in R/R HL and 74% in R/R sALCL. • ‘Real-world’ safety was similar to that reported in the pivotal phase 2 trials.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2015.03.011